

PRESS RELEASE

ValenzaBio Engages ProBioGen For a Second Service Project

Berlin, Germany and Bethesda, MD, USA, June 14, 2022

ProBioGen and ValenzaBio jointly announce today that they have entered into a second service agreement.

The new project is a continuation of successfully completed cell line development work that utilized ProBioGen's proprietary technologies. The new program includes upstream and downstream process development and large-scale GMP production. In addition, ProBioGen's cell and tissue services department will develop several cell-based bioassays to thoroughly characterize the molecule. Under the previous license agreement, ProBioGen is eligible to receive milestone payments. Further financial details were not disclosed.

"We are excited to continue our collaboration with ProBioGen," said Tatyana Touzova, Chief Operating Officer of ValenzaBio. "As the leading experts in cell line development and originators of the [GlymaxX®](#) technology, which offers the benefits of ADCC enhancement in mAb, ProBioGen continues to demonstrate its role as a key player in this industry. With the proficiency of ProBioGen's manufacturing and bioanalytical teams, we are eager to advance the VB119 program to the commercial level."

"We are happy to continue the journey with ValenzaBio. It shows again that our services and technologies as well as our high-quality work are successful. Supporting our clients on their way to the clinic in the best possible way is embedded in our mission to facilitate today the development of medicines for tomorrow – even for diseases that are not yet curable.", added Dr. Gabriele Schneider, ProBioGen's Chief Business Officer.

About ProBioGen

[ProBioGen](#) is a Berlin-based specialist for developing and manufacturing complex therapeutic glycoproteins.

Combining both state-of-the-art development services, based on ProBioGen's [CHO.RiGHT®](#) expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties.

Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).

ProBioGen has been operational for more than 25 years. At three locations in Berlin, more than 250 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work.

About ValenzaBio

[ValenzaBio](#) is a privately held biopharmaceutical company developing safe and effective therapies for autoimmune and inflammatory diseases. The company is advancing a pipeline of differentiated monoclonal antibodies with best-in-class properties, targeting clinically validated mechanisms of action, to provide improved treatment options for patients.

VB119 is ValenzaBio's leading program which is currently enrolling trials in renal autoimmune indications, followed by VB421 which entered clinical trials for thyroid eye disease earlier this year. A third program, VB 517 is expected to begin clinical trials in 2023. ValenzaBio is based in Bethesda, MD.

ProBioGen Contact:
Dr. Gabriele Schneider
Chief Business Officer
cdmo@probiogen.de

ProBioGen Press Contact:
Sarah Wandrey
Corporate Communications
press@probiogen.de

ValenzaBio Contact:
Alicia Davis
THRUST Strategic Communications
alicia@thrustsc.com